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National Black HIV/AIDS Awareness 
Day — February 7, 2020
National Black HIV/AIDS Awareness Day (NBHAAD) 
is observed each year on February 7 to highlight the 
continuing disproportionate impact of human immuno-
deficiency virus (HIV) infection and acquired immuno-
deficiency syndrome (AIDS) on the U.S. black or African 
American (black) population. During 2018, blacks rep-
resented 13% of the U.S. population but accounted for 
43% of all newly diagnosed HIV infections (1).
In February 2019, a new national initiative, Ending the 
HIV Epidemic: A Plan for America (EHE), was proposed. The 
plan calls for intensified efforts to diagnose, treat, prevent, and 
respond to HIV infections in the United States, with an overall 
goal of reducing new HIV infections by ≥90% by 2030 (2).
A study reported in this MMWR issue presents data on 
CDC-funded HIV testing and outcomes among blacks 
who were tested in jurisdictions that are the initial focus of 
EHE. In these jurisdictions during 2017, blacks accounted 
for 43.2% of CDC-funded tests and 49.1% of newly 
diagnosed HIV infections (3). CDC supports a range of 
efforts for reducing the risk for acquiring or transmitting 
HIV infection among blacks. Additional information is 
available at https://www.cdc.gov/hiv/group/racialethnic/
africanamericans. Information about NBHAAD is available 
at https://www.cdc.gov/hiv/library/awareness/nbhaad.html. 
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HIV Testing Outcomes Among Blacks 
or African Americans — 50 Local U.S. 
Jurisdictions Accounting for the 
Majority of New HIV Diagnoses and 
Seven States with Disproportionate 
Occurrences of HIV in Rural Areas, 2017
Aba D. Essuon, PhD1; Hui Zhao, MS2; Guoshen Wang, MS1; Nicoline 
Collins, MPH1; Debra Karch, PhD1; Shubha Rao, MPH1
Identifying persons with human immunodeficiency virus 
(HIV) infection who are unaware of their status and linking 
them to care are critical steps in achieving viral suppression 
and reducing the risk for transmitting HIV (1). In 2017, 
43% of new diagnoses of HIV infection were among persons 
who self-identify as blacks or African Americans (blacks) (2), 
who represent 13% of the U.S. population (3). Fewer blacks, 
compared with whites, were linked to HIV medical care within 
90 days of diagnosis, retained in care, or virally suppressed (4). 
Ending the HIV Epidemic (EHE) is an initiative intended to 
reduce new HIV infections by 90% from 2020 to 2030 (5). 
EHE’s Phase 1 is focused on 50 jurisdictions* that accounted 
* https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview.
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for >50% of new diagnoses during 2016–2017 and seven 
states† with disproportionate HIV prevalence in rural areas 
(5). The purpose of this analysis was to examine HIV testing 
outcomes among blacks in high prevalence EHE jurisdic-
tions, using CDC’s 2017 National HIV Prevention Program 
Monitoring and Evaluation data. Blacks accounted for 43.2% 
of CDC-funded tests and 49.1% of new diagnoses of HIV 
infection. Seventy-nine percent of blacks with newly diagnosed 
HIV infection were linked to HIV medical care within 90 days 
(below the 2010 National HIV/AIDS Strategy goal of 85%), 
71.4% interviewed for partner services, and 81.8% referred to 
prevention services. To achieve the goals of EHE, HIV preven-
tion programs should focus on locally tailored evidence-based§ 
testing strategies to enhance and overcome barriers for linkage 
to and retention in care and reduce onward HIV transmission 
and HIV-related disparities.
CDC analyzed 2017 HIV testing, linkage to care, and part-
ner services data submitted to the National HIV Prevention 
Program Monitoring and Evaluation system by 61 CDC-
funded health departments¶ and 150 CDC-directly funded 
† Seven states: Alabama, Arkansas, Kentucky, Mississippi, Missouri, Oklahoma, 
and South Carolina.
§ https://effectiveinterventions.cdc.gov; https://www.cdc.gov/hiv/research/
interventionresearch/compendium/lrc/index.html.
¶ CDC-funded health departments include 50 states, the District of Columbia, 
Puerto Rico, the U.S. Virgin Islands, and the following eight metropolitan 
statistical areas or specified metropolitan divisions: Baltimore, Chicago, Fulton 
County (Atlanta), Houston, Los Angeles County, New York City, Philadelphia, 
and San Francisco.
community-based organizations. Valid HIV tests were those 
with confirmed HIV-positive test results (discordant and 
indeterminate test results were excluded). Persons with new 
diagnoses were those whose HIV test results were positive dur-
ing the current test and were not previously reported in the 
health department’s HIV surveillance system or had reported 
not having had a previous HIV-positive test result. The per-
centage of positive tests (positivity) for new diagnoses was 
calculated by dividing the number of new HIV-positive tests by 
the number of valid tests. Data were stratified by age, gender, 
race/ethnicity, test setting, U.S. census region, and subpopula-
tion (i.e., men who have sex with men [MSM], persons who 
inject drugs, heterosexual men, and heterosexual women).** 
In non–health care settings, data to identify subpopulations 
were required for all tests conducted; in health care settings 
data were required only for persons with HIV-positive test 
results. Subpopulation data included in the analysis were only 
from non–health care settings.†† The following HIV testing 
outcomes were analyzed among blacks with newly diagnosed 
 ** MSM includes males who reported male-to-male sexual contact; and males 
who reported both male-to-male sexual contact and injection drug use in the 
past 12 months. Persons who inject drugs include persons who reported 
injection drug use in the past 12 months. Heterosexual men includes males 
who only reported heterosexual contact with a female in the past 12 months. 
Heterosexual women includes females who only reported heterosexual contact 
with a male in the past 12 months.
 †† Non–health care settings include HIV testing sites; community setting 
(various, shelter/transitional housing, syringe services program, other); 
correctional facilities (non–health care); health department (field visit); and 
other non–health care.
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HIV infection: linkage to HIV medical care (e.g., attend first 
medical appointment) within 90 days of positive test result; 
interview for partner services (i.e., soliciting information 
from persons with HIV-positive test results regarding sex and 
drug-injecting partners to notify them of potential exposure 
and offer services); and referral to HIV prevention services 
(i.e., behavioral interventions and risk-reduction counseling). 
Percentages of HIV testing outcomes among blacks were cal-
culated by dividing the number in which “yes” was indicated 
for the HIV testing outcomes (linked to care within 90 days, 
interviewed for partner services, and referred to prevention ser-
vices) by the number of HIV-positive tests. Missing data were 
excluded from all outcome denominators. SAS (version 9.4; SAS 
Institute) was used to conduct all analyses.
During 2017, a total of 3,110,049 CDC-funded tests were 
conducted in the United States, including 1,954,741 (62.9%) 
in Phase-1 jurisdictions (Table 1). The highest percentages of 
HIV tests conducted in EHE Phase-1 jurisdictions were among 
persons aged 20–29 years (36.0%), males (52.3%), and those 
residing in the South Census region (57.0%). Blacks accounted 
for 43.2% (844,819) of tests conducted in Phase-1 jurisdic-
tions, twice that of whites (21.6%; 421,656) or Hispanics/
Latinos (22.4%; 437,635). Among all new HIV diagnoses, 
68.9% (8,154 of 11,843) occurred in Phase-1 jurisdictions, 
and the highest percentages of new HIV diagnoses were among 
persons aged 20–29 years (42.9%), males (83.4%), blacks 
(49.1%), and persons residing in the South Census region 
(49.1%). The percentage of blacks with newly diagnosed HIV 
infection (0.5%) was equal to that of Hispanics/Latinos (0.5%) 
and nearly twice that of whites (0.3%) and Asians (0.3%).
In 2017 CDC-funded testing programs identified 11,427 
persons with a previous diagnosis of HIV infection who 
were not known to be in care, 8,917 (78.0%) of whom were 
in Phase-1 jurisdictions. Persons with a previous diagnosis 
who were not known to be in care were predominately aged 
20–29 years (30.2%) or 30–39 years (27.7%), male (78.1%), 
black (58.5%), and residents of the South Census region 
(62.0%). The number of blacks in Phase-1 jurisdictions with a 
previous diagnosis and not known to be in care (5,214; 58.5%) 
was more than three times that of whites (1,516; 17.0%) and 
Hispanics/Latinos (1,359; 15.2%).
Among the 844,819 blacks tested in Phase-1 jurisdictions in 
2017, 37.7% (318,835) were persons aged 20–29 years; 49.7% 
were males; and 63.2% were persons residing in the South 
(Table 2). Of the 4,007 blacks who received a new diagnosis 
of HIV infection, the percentage positivity was highest among 
persons aged 20–29 years (0.6%), males (0.7%), and persons 
residing in the West Census region (0.7%). Among blacks who 
received a new diagnosis, 79.2% were linked to care within 
90 days, 71.4% were interviewed for partner services, and 
81.8% were referred to HIV prevention services. By region, 
linkage of blacks with newly diagnosed HIV infection to medi-
cal care within 90 days was lowest in the West (71.7%), whereas 
the lowest percentages of partner services interviews (58.9%) 
and referrals to HIV prevention services (70.2%) were in the 
Midwest. By subpopulation, the highest percentage of tests 
conducted in EHE jurisdictions were among MSM (27.4%) 
(Table 1), who also had the highest rates of HIV-positive test 
results (3.3%) among subpopulation blacks (Table 2).
Black MSM accounted for 15.0% (31,508 of 209,843) of 
tests and 64.9% (1,030 of 1,587) of new HIV diagnoses in 
non–health care settings. More than 70% of black MSM with 
newly diagnosed HIV infection were linked to HIV medical 
care (80.6%), interviewed for partner services (71.3%), or 
referred to HIV prevention services (84.2%) (Table 2).
Discussion
The goal of HIV testing programs is to identify persons with 
HIV infection who are unaware of their status and to link all 
persons with HIV-positive test results to services. In 2017, 
62.9% of CDC-funded tests and 68.9% of new diagnoses of 
HIV infection were in Phase-1 jurisdictions, among whom 
blacks accounted for >40% of tests (40.4%) and new diagnoses 
(47.5%). Blacks also accounted for 58.5% of persons with a 
previous diagnosis not known to be in care. Compared with 
whites, a higher percentage of blacks in Phase-1 jurisdictions 
received a new diagnosis (49.1%) or had previously received a 
diagnosis and were not known to be in care (58.5%).
This analysis found that HIV testing services supported 
by CDC funding are an important resource for identifying 
persons with new and previously diagnosed HIV infection 
who are not in care, especially in Phase-1 jurisdictions. Testing 
sites in Phase-1 jurisdictions are especially critical for blacks, 
who account for the largest numbers of persons tested, new 
diagnoses of HIV infection, and persons previously diagnosed 
not known to be in care. Factors such as stigma, comorbidi-
ties, and socioeconomic inequalities might increase blacks’ risk 
for acquiring or transmitting HIV and limit access to quality 
health care, housing, and HIV prevention messaging (3). 
Delayed entry into HIV prevention and treatment, especially 
among blacks, leads to worse HIV care outcomes (e.g., delayed 
linkage to care and viral suppression) (6). Although 79.2% of 
blacks with newly diagnosed HIV infection in Phase-1 juris-
dictions were linked to HIV medical care within 90 days, this 
percentage was below the 2010 National HIV/AIDS Strategy 
(NHAS) goal of 85% (7). This outcome suggests that the 2020 
NHAS goals of 85% linkage within 30 days of diagnosis (7) 
and the EHE initiative to reduce new HIV infections by 90% 
by 2030 (7) might be challenging to achieve among blacks 
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TABLE 1. Human immunodeficiency virus (HIV) tests, new diagnoses, and previous diagnoses, by demographic characteristics and subpopulations — 
CDC-funded Phase-I Ending the HIV Epidemic (EHE) jurisdictions* and other CDC-funded testing sites, United States, 2017
Characteristic
Valid CDC-funded HIV tests New HIV diagnoses
Previous HIV diagnoses not 
currently in care
CDC-funded 
tests
CDC-funded tests, 
EHE jurisdictions
New 
diagnoses
New diagnoses, 
EHE jurisdictions
New HIV positivity, 
EHE jurisdictions
Previous 
diagnoses
Previous HIV 
diagnoses not known 
to be in care
No. No. (Col %) No. No. (Col %) (%) No. No. (Col %)
Age group (yrs)†
13–19 218,293 123,447 (6.3) 434 279 (3.4) 0.2 180 142 (1.6)
20–29 1,175,736 704,303 (36.0) 5,221 3,494 (42.9) 0.5 3,345 2,696 (30.2)
30–39 762,944 479,073 (24.5) 3,249 2,322 (28.5) 0.5 3,204 2,467 (27.7)
40–49 416,566 276,244 (14.1) 1,484 1,033 (12.7) 0.4 2,134 1,674 (18.8)
≥50 501,096 355,855 (18.2) 1,411 993 (12.2) 0.3 2,550 1,926 (21.6)
Gender§
Male 1,575,493 1,021,993 (52.3) 9,897 6,801 (83.4) 0.7 8,898 6,967 (78.1)
Female 1,498,393 906,192 (46.4) 1,701 1,168 (14.3) 0.1 2,288 1,744 (19.6)
Test setting
Health care facility 2,388,928 1,502,673 (76.9) 7,280 4,863 (59.6) 0.3 8,352 6,754 (75.7)
Non–health care facility 712,278 451,247 (23.1) 4,539 3,290 (40.3) 0.7 3,05 2,159 (24.2)
U.S. Census region¶
Northeast 471,609 266,101 (13.6) 1,707 1,216 (14.9) 0.5 1,421 1,015 (11.4)
Midwest 397,121 261,005 (13.4) 1,661 1,136 (13.9) 0.4 1,765 1,589 (17.8)
South 1,792,105 1,114,464 (57.0) 6,108 4,007 (49.1) 0.4 7,283 5,530 (62.0)
West 416,921 303,177 (15.5) 2,144 1,691 (20.7) 0.6 827 722 (8.1)
U.S. dependent areas 32,293 9,994 (0.5) 223 104 (1.3) 1.0 131 61 (0.7)
Race/Ethnicity**
White 819,524 421,656 (21.6) 2,330 1,378 (16.9) 0.3 2,104 1,516 (17.0)
Black or African American 1,257,198 844,819 (43.2) 5,622 4,007 (49.1) 0.5 6,403 5,214 (58.5)
Hispanic or Latino 677,954 437,635 (22.4) 2,974 2,076 (25.5) 0.5 1,913 1,359 (15.2)
Asian 73,379 53,066 (2.7) 223 164 (2.0) 0.3 133 112 (1.3)
AI/AN 16,269 7,519 (0.4) 59 27 (0.3) 0.4 39 24 (0.3)
H/PI 6,509 4,176 (0.2) 15 13 (0.2) 0.3 14 12 (0.1)
Multirace 23,935 12,497 (0.6) 134 90 (1.1) 0.7 76 51 (0.6)
Subpopulation in non–health care setting††
MSM 180,748 123,635 (27.4) 3,175 2,326 (70.7) 1.9 1,602 1,204 (55.8)
Transgender persons 7,763 5,377 (1.2) 109 89 (2.7) 1.7 70 55 (2.5)
Persons who inject drugs 38,190 17,142 (3.8) 145 98 (3.0) 0.6 121 68 (3.1)
Heterosexual men 173,259 100,521 (22.3) 443 305 (9.3) 0.3 424 265 (12.3)
Heterosexual women 182,852 108,053 (23.9) 376 262 (8.0) 0.2 350 248 (11.5)
Total 3,110,049 1,954,741 (100.0) 11,843 8,154 (100.0) 0.4 11,427 8,917 (100.0)
Abbreviations: AI/AN = American Indian or Alaska Native; Col = column; H/PI = Native Hawaiian or Pacific Islander; MSM = gay, bisexual, and other men who have 
sex with men.
 * Fifty local jurisdictions accounting for >50% of new diagnoses during 2016–2017 and seven states with disproportionate occurrence of HIV in rural areas.
 † For age, the numbers of records missing or invalid are as follows: in the columns “Valid CDC-funded HIV tests,” 35,414 (1.1%) of all CDC-funded valid HIV tests and 
15,819 (0.8%) of valid HIV tests in EHE jurisdictions; in the columns under “New HIV diagnoses,” 44 (0.4%) of total new diagnoses and 33 (0.4%) of new diagnoses 
in EHE jurisdictions; in the columns under “Previous HIV diagnoses,” 14 (0.1%) of total previous diagnoses and 12 (0.1%) of previous diagnoses in EHE jurisdictions.
 § For gender, the numbers of records reported as transgender, missing, or invalid are as follows: in the columns under “Valid CDC-funded HIV tests,” 36,163 (1.2%) of 
all CDC-funded valid HIV tests and 26,556 (1.4%) of valid HIV tests in EHE jurisdictions; in the columns under “New HIV diagnoses,” 245 (2.1%) of total new diagnoses 
and 185 (2.3%) of new diagnoses in EHE jurisdictions; in the columns under “Previous HIV diagnoses,” 241 (2.1%) of total previous diagnoses and 206 (2.3%) of 
previous diagnoses in EHE jurisdictions.
 ¶ Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; Midwest: Illinois, Indiana, Iowa, 
Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; South: Alabama, Arkansas, Delaware, District of Columbia, 
Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia; West: Alaska, 
Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming.
 ** For race/ethnicity, the numbers of records missing or invalid are as follows: in the columns under “Valid CDC-funded HIV tests,” 235,281 (7.6%) of all CDC-funded 
valid HIV tests and 173,373 (8.9%) of valid HIV tests in EHE jurisdictions; in the columns under “New HIV diagnoses,” 486 (4.1%) of total new diagnoses and 399 
(4.9%) of new diagnoses in EHE jurisdictions; in the columns under “Previous HIV diagnoses,” 745 (6.5%) of total previous diagnoses and 629 (7.1%) of previous 
diagnoses in EHE jurisdictions.
 †† MSM include males who reported male-to-male sexual contact as well as males who reported both male-to-male sexual contact and injection drug use in the 
past 12 months. Persons who inject drugs include persons who reported injection drug use in the past 12 months. Heterosexual males include males who only 
reported sexual contact with a female in the past 12 months. Heterosexual females include females who only reported sexual contact with a male in the past 
12 months. Data on subpopulations were limited to those tested in non–health care settings. For subpopulation in non–health care settings, the numbers of 
records missing or invalid are as follows: in the columns under “Valid CDC-funded HIV tests,” 129,466 (18.2%) of all CDC-funded valid HIV tests and 96,519 (21.4%) 
of valid HIV tests in EHE jurisdictions; in the columns under “New HIV diagnoses,” 291 (6.4%) of total new diagnoses and 210 (6.4%) of new diagnoses in EHE 
jurisdictions; in the columns under “Previous HIV diagnoses,” 483 (15.8%) of total previous diagnoses and 319 (14.8%) of previous diagnoses in EHE jurisdictions. 
Totals for subpopulation in non–health care settings are 712,278 for all CDC-funded HIV tests, 451,247 for CDC-funded tests in EHE jurisdictions, 4,539 for total 
new HIV diagnoses, 3,290 for new diagnoses in EHE jurisdictions, 3,050 for previously diagnosed, and 2,159 for previously diagnosed in EHE jurisdictions.
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TABLE 2. Linkage to human immunodeficiency virus (HIV) medical care for blacks or African Americans (blacks) with newly diagnosed HIV 
infection — CDC-funded Phase-I Ending the HIV Epidemic (EHE) jurisdictions,* United States, 2017
Characteristic
No. (%)
CDC-funded tests 
among blacks in EHE 
jurisdictions
New diagnoses among 
blacks in EHE 
jurisdictions
Linked to HIV medical 
care within 90 days of 
diagnoses
Interviewed for 
partner services
Referred to HIV 
prevention services
Age group at test (yrs)†
13–19 59,683 183 (0.3) 117 (84.2) 88 (71.0) 122 (84.7)
20–29 318,835 1,869 (0.6) 1,257 (81.3) 1,041 (74.6) 1,301 (83.2)
30–39 193,353 1,013 (0.5) 685 (78.8) 549 (70.7) 679 (81.1)
40–49 110,772 429 (0.4) 262 (74.4) 215 (70.0) 267 (78.1)
≥50 158,462 501 (0.3) 301 (74.5) 225 (62.0) 322 (80.7)
Gender§
Male 419,746 3,124 (0.7) 2,039 (79.2) 1,660 (71.8) 2,124 (82.4)
Female 420,203 785 (0.2) 517 (78.6) 407 (69.8) 499 (79.6)
Test setting
Health care facility 634,620 2,420 (0.4) 1,644 (80.2) 1,370 (72.7) 1,554 (81.7)
Non–health care facility 209,843 1,587 (0.8) 980 (77.6) 749 (69.2) 1,139 (82.0)
U.S. Census region¶
Northeast 115,415 586 (0.5) 447 (86.3) 384 (83.8) 473 (83.9)
Midwest 139,838 675 (0.5) 430 (77.0) 331 (58.9) 448 (70.2)
South 534,304 2,378 (0.4) 1,539 (79.0) 1,200 (74.3) 1,570 (86.6)
West 55,260 368 (0.7) 208 (71.7) 204 (61.1) 202 (73.2)
U.S. dependent areas 2 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Subpopulation in non–health care setting**
MSM 31,508 1,030 (3.3) 664 (80.6) 484 (71.3) 763 (84.2)
Transgender 1,964 52 (2.6) 34 (79.1) 28 (73.7) 41 (85.4)
Persons who inject drugs 3,139 26 (0.8) 8 (42.1) 9 (47.4) 18 (72.0)
Heterosexual males 56,676 186 (0.3) 113 (74.8) 97 (65.1) 132 (80.0)
Heterosexual females 64,160 189 (0.3) 114 (75.0) 92 (74.8) 125 (77.6)
Total 844,819 4,007 (0.5) 2,624 (79.2) 2,119 (71.4) 2,693 (81.8)
Abbreviation: MSM = gay, bisexual, and other men who have sex with men.
 * Fifty local jurisdictions accounting for >50% of new diagnoses during 2016–2017 and seven states with disproportionate occurrence of HIV in rural areas.
 † For age, the numbers of records missing or invalid are as follows: in the column “CDC-funded tests among blacks in EHE jurisdictions,” 3,714 (0.4%); in the column 
“New HIV diagnoses among blacks in EHE jurisdictions,” 12 (0.3%); in the column “Linked to HIV medical care within 90 days of diagnoses,” 2 (0.1%); in the column 
“Interviewed for partner services,” 1 (0.05%); in the column “Referred to HIV prevention services,” 2 (0.1%).
 § For gender, the numbers of records reported as transgender, missing, or invalid are as follows: in the column “CDC-funded tests among blacks in EHE jurisdictions,” 
4870 (0.6%); in the column “New HIV diagnoses among blacks in EHE jurisdictions,” 98 (2.4%); in the column “Linked to HIV medical care within 90 days of diagnoses,” 
68 (2.6%); in the column “Interviewed for partner services,” 52 (2.5%); in the column “Referred to HIV prevention services,” 70 (2.6%).
 ¶ Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; Midwest: Illinois, Indiana, Iowa, 
Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; South: Alabama, Arkansas, Delaware, District of Columbia, 
Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia; West: Alaska, 
Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming.
 ** MSM include males who reported male-to-male sexual contact as well as males who reported both male-to-male sexual contact and injection drug use in the past 
12 months. Persons who inject drugs include persons who reported injection drug use in the past 12 months. Heterosexual males include males who only reported 
heterosexual contact with a female in the past 12 months. Heterosexual females include females who only reported heterosexual contact with a male in the past 
12 months. Data on behavioral risk factors used to define the subpopulation were limited to those tested in non–health care settings. For subpopulation in non–
health care settings, the numbers of records missing or invalid are as follows: in the column “CDC-funded tests among blacks in EHE jurisdictions,” 52,396 (25.0%); 
in the column “New HIV diagnoses among blacks in EHE jurisdictions,” 104 (6.6%); in the column “Linked to HIV medical care within 90 Days of diagnoses,” 47 (4.8%); 
in the column “Interviewed for partner services,” 39 (5.2%); in the column “Referred to HIV prevention services,” 60 (5.3%). Totals for subpopulation in non–health 
care settings are 209,843 for CDC-funded tests among blacks in EHE jurisdictions, 1,587 for new diagnoses among blacks in EHE jurisdictions, 980 for linked to HIV 
medical care within 90 days of diagnoses, 749 for interviewed for partner services, and 1,139 for referred to HIV prevention services.
without expanding current efforts and implementing novel 
testing strategies.
The findings in this report are subject to at least four limita-
tions. First, the findings are based on data from CDC-funded 
tests, which are not representative of all U.S. HIV testing. 
Second, estimates of persons with newly diagnosed HIV 
infection rely on verification using CDC’s HIV surveillance 
data or self-report, which could result in an overestimation 
of new diagnoses. Third, data on linkage to HIV medical 
care, interview for partner services, and referral to HIV pre-
vention services exclude missing data from the denominator 
and likely overestimate the percentage of persons receiving 
services. Finally, data on subpopulations are collected for all 
tests in non–health care settings but only for HIV-positive 
tests in health care settings, resulting in underreporting of 
tests among subpopulations. 
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Summary
What is already known about this topic?
Ending the HIV Epidemic (EHE) jurisdictions are disproportion-
ately affected by human immunodeficiency virus (HIV).
What is added by this report?
In 2017, blacks accounted for >40% of those tested and new 
diagnoses in EHE jurisdictions. Compared with whites, more 
blacks in EHE jurisdictions received a new diagnosis or were 
identified as a person with previously diagnosed HIV infection.
What are the implications for public health practice?
HIV prevention programs focused on locally tailored innovative 
testing, linkage, reengagement, and prophylaxis and treatment 
for blacks could help to achieve the national goals to end the 
HIV epidemic in the United States.
CDC-funded HIV testing programs are identifying new and 
previously diagnosed HIV infections in persons not known 
to be in care in Phase-1 jurisdictions, but challenges linking 
persons with new and previously diagnosed infections to care 
differ (8). Broader implementation of routine HIV screening 
and HIV-related services, most notably among black MSM, 
has critical public health implications. To achieve the goals 
of the EHE initiative, HIV prevention programs will need to 
focus on locally tailored evidence-based testing strategies to 
overcome barriers for and enhance linkage to and retention in 
care, provide prophylaxis and treatment, and reduce onward 
HIV transmission and HIV-related disparities.
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